

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab)
Recombinant Antibody
Catalog # APR10097****Specification**

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P32970
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.1 KDa

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Additional Information**Target/Specificity**

TNFSF7 / CD27L / CD70

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protein Information**Name** CD70 ([HGNC:11937](#))**Function**

Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:28011863, PubMed:28011864, PubMed:8387892). The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:28011863, PubMed:28011864).

Cellular Location


Cell membrane; Single-pass type II membrane protein

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) is more than 99.29% ,determined by SEC-HPLC.



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC150=0.06731 µg/mL



The endocytosis ratio vorsetuzumab by 786-O increased with the increase of antibody concentration, and the Internalization Rate (%) reached 55% at antibody concentration of 0.67 nM.